Novo Nordisk (NYSE: NVO)
Novo Nordisk Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novo Nordisk Company Info
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
News & Analysis
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
The Largest Healthcare Companies by Market Cap in July 2025
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
2 S&P 500 Dividend Stocks That Could Climb 17% or More, According to Wall Street
2 Stocks to Buy on the Dip and Hold for 10 Years
How to Invest in Mounjaro
Why Shares in Novo Nordisk Lost Weight Today
How to Invest in Ozempic
Valuation
Earnings Transcripts
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
NVO earnings call for the period ending December 31, 2024.
Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2024.
Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2024.
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.